Healthcare
Virbac S.A.(VRBCF)
Live Price
Offline$408.00
+0.00% today
1Y Change
+17.92%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $3.04B
- Revenue Growth
- +4.8%
- EPS Growth
- +3.6%
- Dividend Yield
- 0.4%
Coverage: 251 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Virbac S.A. (VRBCF) is a Healthcare stock with a market cap of $3.04B and listed on OTC. The stock last traded around $408.00 and up 17.9% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +4.8%, EPS growth of +3.6%, a dividend yield of 0.4%. What stands out right now is revenue +4.8%, EPS +3.6%, free cash flow -16.5% with operating margin 14.9% and ROIC 10.0%. The dividend is present but secondary, with a yield around 0.4%. Valuation is more restrained than many high-expectation growth names at P/E 20.2 and price/sales 2.1. Stock Foundry combines VRBCF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
+4.8% vs +7.6% peer median
Operating Margin
Below sector median
+14.9% vs +19.4% peer median
P/E
Below sector median
20.2 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report was closer to in-line
2026 was reported on Mar 17, 2026 with revenue ahead of estimates by +87.7%.
The operating story is still moving forward
Revenue is running at +4.8% and EPS at +3.6%, with operating margin around 14.9%.
The next real check-in already has a date
The next earnings event is scheduled for Sep 9, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +3.7% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Mar 17, 2026 | โ | +0.0% | +11.2% | +11.2% |
2025 Sep 12, 2025 | โ | +0.0% | +0.0% | +0.0% |
2025 May 13, 2025 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VRBCF
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
VRBCF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for VRBCF and SPY.
Company Overview
Virbac S.A.
Other OTC
Virbac SA manufactures and sells a range of products and services for companion and food-producing animals in France, Europe, Latin America, North America, the Asia Pacific, the Middle East, and Africa. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
- Leadership
- Habib Ramdani
- IPO Date
- Apr 17, 2013
- Employees
- 6.4k
- Street Address
- 13e rue LID - BP 27
- Mailing
- Carros, 06511
- Region
- Carros, FR
- Reporting Currency
- USD
- Investor Line
- 33 4 92 08 71 00
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 20.2
- EV/EBITDA
- 11.5
- Price/Sales
- 2.1
- Price/Book
- 2.7
Growth
- Revenue
- +4.8%
- EPS
- +3.6%
- Free Cash Flow
- -16.5%
Profitability
- Gross Margin
- 35.4%
- Operating Margin
- 14.9%
- Net Margin
- 10.3%
- ROE
- 13.8%
- ROIC
- 10.0%
Balance Sheet
- Debt/Equity
- 0.26
- Current Ratio
- 1.53
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.